The report covers the detailed analysis of the trends, future estimations, and a thorough study of the global mosquito repellent market on the basis of type and distribution channel. It analyses government regulations, policies, and patents to provide information on the current market trends and suggests future growth opportunities. This in turn increases consumer acceptance globally. The study highlights Porter’s five forces analysis to determine the factors affecting the market growth. These factors include raw material prices, intense competition, end users, manufacturers, and suppliers. To understand the market, drivers, restraints, and opportunities are explained in the report. Furthermore, it includes the revenue generated from the sales of footwear across North America, Europe, Asia-Pacific, and LAMEA.

The report provides dynamics, estimations, trends, and forecast related to the global negative pressure wound therapy (NPWT) devices market. This report estimates revenue of a company generated from the direct sales of NPWT devices. However, it does not include the revenue generated by dealers, traders, or brokers involved in the supply of these products to hospitals or clinics for wound treatment. Furthermore, revenue generated from the consulting services provided by doctors at hospitals and clinics is excluded from the report. NPWT devices generate sub-atmospheric pressure to heal acute & chronic wounds and promote recovery of second- and third-degree burns. Two types of devices, namely, V.A.C. ULTA Therapy System marketed by 3M (Acelity L.P. Inc.), RENASYS system marketed by Smith & Nephew plc, are majorly used for healing wounds such as ulcers, burns, and surgical wounds. The negative pressure wound therapy devices market is segmented into product, wound type, end user, and region. On the basis of product, it is classified into conventional NPWT devices and single use disposable NPWT devices. Thus, the report contains the estimations of revenue generated from these two types of devices in the market. The market is divided in these two types of devices to provide a better understanding about the type of NPWT devices that are significantly growing in the market. Furthermore, on the basis of wound type, the market is bifurcated into chronic and acute wounds. This segmentation provides an idea about the use of NPWT devices in the market. Similarly, on the basis of end user, it is divided into hospitals & clinics, ambulatory surgical centers (ASCs), and home care settings.

A menstrual cup is a feminine hygiene product that are used during menstruation. It is inserted into the vagina and one can keep it inside for maximum 12 hours. Its purpose is to prevent menstrual blood from leaking onto the clothes. It is made up of either latex, silicone, or thermoplastic elastomer. Silicon and thermoplastic elastomer are hypoallergic which means that the wearer can be safe from unwanted irritation and allergies. The menstrual cups are available in a smaller and a larger size, where smaller size is recommended for women under 30 (who have not given birth vaginally) and the larger size is recommended for women who are over 30 (have given birth vaginally or have a heavy flow). The scope of the study is intended to discuss the upcoming and present market trends of menstrual cup. The study provides the revenue generated by the sales of menstrual cups that are used to manage menstruation. It does not include the sales of other feminine hygiene products such as sanitary napkins and tampons. In addition, this report details current market trends, drivers, restraints, and opportunities and determines the future growth potential of the global menstrual cup products market.

The report provides market dynamics and trends related to the global meningococcal vaccines market. In addition, it presents the estimations and forecast of the market. The estimation includes revenue generated by the revenue generated through sales of meningococcal vaccines, which are used for immunization against different serotypes. Along with sales revenue, demand and supply for meningococcal vaccines across the globe are considered during market estimation. The valuations comprise revenue generated from the sales of the meningococcal vaccines directly from the company. However, it does not include the revenue generated by dealers, traders, or brokers of the market during the supply of these vaccines in hospitals or laboratories. In addition, the report excludes revenue generated from sales of meningococcal vaccine services.

The macular degeneration treatment market is largely driven by rise in the incidence of retinal disorders and growing geriatric population across the world. The aging population is more likely to witness par tial loss of vision, abnormality where straight lines appear wavy, blurred vision, distorted vision, inability to witness in dim light, or spots and other macular degeneration disorders associated with pain. Between 25% and 50% of the community-dwelling elderly have been witnessing several retinal problems since the past few years. According to the data published in the European Society of Retina Specialists (EURETINA), currently, in Europe, an estimated number of 33.6 million persons over the age of 60 years are suffering from AMD. The increasing number of individuals suffering from retinal disorders is directly proportional to the market’s growth. This high prevalence rate denotes the importance of AMD treatment, primarily for treating the target disease. Furthermore, the increasing R&D investments and rising approvals for new drugs of the treatment are other major factors driving the market’s growth. Furthermore, numerous pharmaceutical manufacturers associated with the AMD market, particularly in emerging markets, such India, Brazil, and other nations witnessed significant growth and capitalized over the past decade.

Microarrays are the most popular form of lab-on-a-chip technology, due to the wide range of differentiation and applications. Increasing use of personal medical devices and the need for immediate results fromdiagnostic tests are the major factors driving the demand formicroarrays in the lab-on-a-chip andmicroarraysmarket. The lab-on-a-chip segment of the market studied is expected to have a positive market growth due to the rise in demand for diagnostics, increasing global population, and technological advancement. Furthermore, the rise in the adoption of personalized medicine and easy accessibility of lab-on-a-chip technology are expected to augment the demand for the same across the world. The technological advances have increased the throughput of device production, improved rapid prototyping efforts, and enabled researchers to enhance the complexity and sophistication of experiments that can be performed on a microfluidic chip. As a result,microfluidic technology has its immense potential for research in life science andmedicine. In the United States, the usage of high-throughput screening (HTS) technologies increased drastically in academic research. With the rising interest in HTS, the lab-on-chip technology is expected to be widely used in the country, due to its applications in high-throughput screening.

The high content screening market is driven by factors, such as an increase in investments by the government and other organizations , technological advancements, and the expanding application areas. According to the Office for National Statistics (ONS), the total expenditure in R&D in the United Kingdom is increasing rapidly. During 2016, the expenditure was GBP 33.2 billion, which increased in 2017 and reached GBP 34.8 billion. Similarly, in the United States, the investment on medical R&D was USD 39.5 billion, in 2017. This indicates that a substantial investments were made in healthcare in the major countries. As the government and other organizations are investing more in research and development, the high content screening market is expected to register significant growth. The increase in R&D activities in Asia, particularly India. The consecutive annual growth in the expenditure in R&D in the country indicates a period of stability, security, and healthy competition across the industrial sectors. The high cost of the advanced technologies is expected to hinder the growth of the market. However, the increasing demand for advanced tools for drug developments, other studies, recent product launches are expected to boost the growth of the high content screening market.

年初至今（2020 年1 月1 日至2020 年9 月10 日），申万医药生物板块上涨43.01%，沪深300 指数上涨11.85%，医药生物板块整体跑赢沪深300 指数31.16 个百分点，涨跌幅在申万28 个一级行业中排名第3 位，医药6 个子板块均以上涨报收；细分来看，具有科技属性的医疗器械和生物制品子板块表现抢眼，分别上涨了71.18%和68.97%；医药板块整体TTM 市盈率剔除负值后为47.15 倍，沪深300 市盈率为13.87 倍，医药板块相对沪深300 的估值溢价率为240%，处于2013 年来的高位水平。

2020年1-8月多数品种实现批签发量稳健增长。新兴事件过后，监管趋严，同时今年疫情导致上半年采浆减少，下半年供给有望趋紧，中长期来看，集中度有望提升，整体未来发展值得看好。8月多数品种批签发量有所下滑。 重点推荐华兰生物、双林生物、卫光生物、天坛生物等，建议关注博雅生物。

流感疫苗进一步放量，本月合计批签发907.77万支，同比增长68.48%，Sanofi进口流感疫苗再获批签发以弥补缺口。Sanofi三价流感疫苗重新批签发393.88万支；金迪克四价流感疫苗获今年首批，累计批签发59.59万；华兰生物四价放量并新增三价批签发，本月批签发四价流感疫苗158.23万，三价流感疫苗69.95万；北京科兴进一步放量，本月批签发三价流感疫苗104.63万；长春所批签发四价流感疫苗19.27万，三价流感疫苗56.39万。